Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Sorafenib As Maintenance Therapy Post Allogeneic...
Conference

Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial

Abstract

Abstract

Authors

Burchert A; Bug G; Finke J; Stelljes M; Rollig C; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G

Volume

132

Publisher

American Society of Hematology

Publication Date

November 29, 2018

DOI

10.1182/blood-2018-99-112614

Conference proceedings

Blood

Issue

Supplement 1

ISSN

0006-4971